Results 21 to 30 of about 49,425 (241)

Remdesivir [PDF]

Hospital Pharmacy, 2021
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Terri L. Levien, Danial E. Baker
  +6 more sources

Clinical Outcomes of Remdesivir in Moderate and Severe Cases of COVID-19: A Retrospective Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Remdesivir is a nucleotide analogue prodrug that perturbs viral replication. Remdesivir has been used in various trials previously for the treatment of Coronavirus Disease 2019 (COVID-19).
Ruth Priya Senthiappan, Archana A Dambal, Mohan Kashinkunti, Kiran R Aithal, Rajendra Kumar Parakh, Bhargav Vuppumalla   +5 more
doaj   +1 more source

Remdesivir-associated bradycardia [PDF]

BMJ Case Reports, 2021
Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac
Patrick R Ching, Calvin Lee
openaire   +3 more sources

Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose. Remdesivir and its active metabolite are predominantly eliminated via renal route; however, information regarding renal uptake transporters is limited.
Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi   +4 more
doaj   +1 more source

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys

Frontiers in Pharmacology, 2021
Aim: Kidney impairment is observed in patients with COVID-19. The effect of anti-COVID-19 agent remdesivir on kidneys is currently unknown. We aimed to determine the effect of remdesivir on renal fibrosis and its downstream mechanisms.Methods: Remdesivir
Lin Xu, Lin Xu, Lin Xu, Lin Xu, Bo Tan, Di Huang, Di Huang, Di Huang, Di Huang, Meijie Yuan, Meijie Yuan, Tingting Li, Tingting Li, Ming Wu, Ming Wu, Ming Wu, Ming Wu, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye   +20 more
doaj   +1 more source

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics

Frontiers in Immunology, 2022
The SARS-CoV-2 virus needs multiple copies for its multiplication using an enzyme RNA-dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the multiplication of the virus, and protects patients.
Bhaswati Chatterjee, Suman S. Thakur
doaj   +1 more source

Ethical Allocation of Remdesivir [PDF]

The American Journal of Bioethics, 2020
As the federal government distributed remdesivir to some of the states COVID-19 hit hardest, policymakers scrambled to develop criteria to allocate the drug to their hospitals.
Crutchfield, Parker, Gibb, Tyler S., Redinger, Michael J., Fales, William   +3 more
openaire   +3 more sources

Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.

PLoS ONE, 2021
ObjectivesRemdesivir is one of the most widely recommended and used medications for COVID-19 treatment. However, different outcomes have been reported for hospitalized patients with COVID-19 treated with remdesivir. Specifically, the effect of the timing
Hawra Ali Hussain Alsayed, Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Qutayba Hamid, Rabih Halwani   +5 more
doaj   +2 more sources

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo .
Chenchula Santenna, Kota Vidyasagar, Krishna Chaitanya Amarneni, Sai Nikhila Ghanta, Balakrishnan Sadasivam, Saman Pathan, R. Padmavathi   +6 more
doaj   +1 more source

Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study

Antibiotics, 2022
The benefits of remdesivir treatment, with or without co-administration of antibiotics such as azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single-center study was to assess the effects of remdesivir, with or without ...
Andrea Ticinesi, Domenico Tuttolomondo, Antonio Nouvenne, Alberto Parise, Nicoletta Cerundolo, Beatrice Prati, Ilaria Zanichelli, Angela Guerra, Nicola Gaibazzi, Tiziana Meschi   +9 more
doaj   +1 more source